ArticleThe patient2026
Responsiveness of the EQ-5D-Y-5L Parent-Proxy Version Among Children with Juvenile Idiopathic Arthritis.
Article in The patient, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundValid and reliable health-related quality of life (HRQoL) instruments are needed in clinical practice to quantify the burden of juvenile idiopathic arthritis (JIA) and capture changes in health over time. We examined the responsiveness of the parent-proxy EuroQol 5-Dimension Youth 5-Level (EQ-5D-Y-5L) instrument in children with JIA.
methodsThis multicenter international cohort study included consecutive children with JIA who were enrolled in the Understanding Childhood Arthritis Network Canadian-Dutch (UCAN CAN-DU) eHealth platform. Demographics, Clinical Juvenile Arthritis Disease Activity Score-10 (cJADAS10) disease activity, Childhood Health Assessment Questionnaire (CHAQ) disability index, and health status were assessed at baseline and at follow-up visits 3-12 months later. Patients were categorized as improved, stable, or deteriorated using cJADAS10 and CHAQ. Responsiveness was evaluated at both the dimension level (distributional change) and continuous score level (EQ-5D-Y-5L level summary score [LSS] and EuroQol Visual Analogue Scale [EQ VAS]) using effect size and standardized response mean (SRM).
resultsA total of 246 patients were included (median age 12 years [interquartile range: 8-15]; 54% female). At the dimension level, children classified as improved showed clear shifts toward lower problem levels across all five EQ-5D-Y-5L dimensions, particularly in physical dimensions, while stable patients showed minimal distributional change. At the continuous score level, improvements were mostly associated with large effect size and SRM for both LSS and EQ VAS (0.8-1.6), whereas changes in stable groups were negligible to small.
conclusionsThe parent-proxy EQ-5D-Y-5L demonstrates responsiveness to clinically defined changes in children with JIA. Its ability to detect improvement while remaining stable in the absence of change supports its use in longitudinal clinical studies and economic evaluations.
Identifiers
42265405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.